Daiichi Suntory Pharma Co., Ltd.

Suntory Limited

Daiichi Suntory Biomedical Research Co., Ltd.

Yoichi Nunokawa

Kenji Suzuki

Masayuki Saitoh

Akira Matsumori

Takashi Nakatsuka

Keiichi Abe

Naohisa Ogou

A substituted benzoic acid derivative which is represented by the following formula (I) and has an NF-&#x3ba;B inhibiting action (in the formula, R, Rand Reach independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an alkoxy group having 1 to 6 carbon(s); Rand Reach independently represents a hydrogen atom, an alkyl group having 1 to 6 carbon(s) or an acyl group having 2 to 11 carbons); Rrepresents an optionally-substituted aromatic hydrocarbon group or an optionally-substituted heterocyclic group; and X represents a carboxyl group which may be esterified or amidated) 

Substituted benzoic acid derivatives having NF-&#x3ba;B inhibiting action

A NF-&#x3ba;B inhibitor represented by the following formula (I) is provided:&#x2003;

NF-&#x3ba;B inhibitor containing substituted benzoic acid derivative as active ingredient

An NF-&#x3ba;B inhibitor having as an active ingredient a benzoquinone derivative represented by the general formula (1) wherein R, R, and Rare each independently H, alkyl having 1 to 5 carbons, or alkoxy having 1 to 5 carbons; Ris H, hydroxymethyl, alkyl, or carboxyl which is optionally esterified or amidated; Z is represented by the formula (A); and, n is an integer from 0 to 6, or its hydroquinone form or a pharmaceutically acceptable salt thereof.

NF-&#x3ba;B inhibitor comprising phenylmethyl benzoquinone as the active ingredient

An inhibitor of NF-&kgr;B comprising as an active ingredient an indan derivative represented by the general formula (I) or a salt thereof.

NF-&kgr;B inhibitor comprising an indan derivative as an active ingredient

Methods of using phenylmethylbenzoquinone and hydroquinone compounds for treatment of myocarditis, dilated cardiomyopathy and heart failure

An expression regulatory sequence comprising a NF-.kappa.B recognition sequence, at least part of the 3'-untranslated region (3'-UTR) and at least part of the 3'-flanking region of human induced nitrogenmonoxide synthase (hiNOS) gene; and a method for screening a substance repressing the activation of NF-.kappa.B, comprising treating cells having the expression regulatory sequence and capable of detecting the activation of NF-.kappa.B with a subject substance, and observing a change in the expression amount of reporter genes.

Growing community of inventors

Toyonaka, Japan

Yoichi Nunokawa